Efinopegdutide
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-alcoholic Steatohepatitis
Conditions
Non-alcoholic Steatohepatitis, Hepatic Impairment
Trial Timeline
Nov 21, 2023 → Dec 5, 2024
NCT ID
NCT06052566About Efinopegdutide
Efinopegdutide is a phase 1 stage product being developed by Merck for Non-alcoholic Steatohepatitis. The current trial status is completed. This product is registered under clinical trial identifier NCT06052566. Target conditions include Non-alcoholic Steatohepatitis, Hepatic Impairment.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06482112 | Phase 2 | Completed |
| NCT06052566 | Phase 1 | Completed |
Competing Products
20 competing products in Non-alcoholic Steatohepatitis